Establishment Labs Grew 34% and Fell 28% From Its High — The Tape Is Arguing With the Press Release

A first-ever positive free cash flow quarter, a raised guide, and U.S. revenue up 119% — met by a stock in a single unbroken 90-day slide. The disagreement lives in the gross-margin line and a cash milestone that quietly moved a year to the right.

ESTA · Earnings Call · 2026-10-29

The best quarter, the worst tape

Establishment Labs did almost everything a growth-medtech investor asks for in Q3 2026. Revenue of $72 million rose 33.9% year over year. Adjusted EBITDA went from $1.2 million to $6.4 million, an 8.9% margin. U.S. revenue more than doubled to $26 million, now 36% of the mix versus 22% a year ago. Guidance went up, to more than $274 million from a prior $269–271 million range, with 25% growth penciled in for 2027. And the company booked its first positive free cash flow in its history: $7.7 million of operating cash flow, $5.1 million free.

Q3 marks our first quarter of positive free cash flow, a major milestone, and we are looking forward to our first year of positive free cash flow in 2027.
Filippo Caldini, Chief Executive Officer · 2026-10-29

Meanwhile the stock has done nothing but fall. The 90-day tape is a single down segment, −21.6%, and the shares sit 28.5% below the July 21 peak of $95.65. A $2 billion market cap that trades at 10.4x revenue on a stock chart that looks like a broken momentum trade is the whole story: the market stopped paying for the growth before the growth stopped.

From land grab to harvest

The most consequential thing management said had nothing to do with a number. It was a change in verb tense. “We ended the quarter with 2,100 accounts. Although we are regularly adding new accounts, our focus is increasingly on utilization within our existing base.” — Filippo Caldini, Chief Executive Officer · 2026-10-29 That is the sound of a U.S. launch maturing. In August 2025 the company was celebrating 1,000 accounts; by February 2026, 1,500-plus; now 2,100. The account curve is flattening and the strategy is shifting to depth — a transition management pre-announced back in February: “2026, the story for us is going to be about continuing to expand the number of accounts that we have in the United States but also going quite a bit deeper into all these accounts.” — Rajbir Denhoy, Chief Financial Officer · 2026-02-24 This was the quarter they could point at proof: 43% average Motiva share of implant procedures among surgeons using it, an 85% reorder rate, and rising average orders per account. The sales force is now 55 reps, up from 43 a year ago and 50 in May. The category-creation argument is also getting harder to dismiss. A survey of 78 Preserve-trained surgeons found ~22% of their augmentations had shifted to the procedure, 88% said it pulled in patients who weren't considering augmentation, and 98% said patients ask for it by name. That is the rare kind of evidence that supports broad adoption rather than a launch pop — and it is why the minimally invasive platform's guide went to more than $40 million from more than $35 million.

The margin line is where the story breaks

Here is the crack. Adjusted gross margin was 70.8%, up 70bp year over year and flattered by the mix shift toward direct U.S. business. Yet full-year guidance came down, from 71.2–72.2% to roughly 70.7%. The cause was not price or cost. It was channel:

This reflects stronger-than-anticipated OUS distributor sales, which generate additional revenue and gross profit dollars, albeit at a lower margin percentage than our direct business.
Cassandra Harris, Chief Financial Officer · 2026-10-29

Distributors were 60% of OUS revenue versus a planned 50% — lumpy, order-timed, lower-quality revenue. Management was explicit that distributor order timing is variable and that they are pushing toward make-to-order. Investors who have watched OUS distributor sales whipsaw from +14.4% to +4.4% to +10% this year can be forgiven for discounting the beat. Add the geopolitical drag — the Middle East conflict impacting order flow, a theme that has been near the top of the global keyword board for two straight quarters — and the OUS print reads as less clean than the headline. This is a company that still runs a leveraged balance sheet: effective net cash of −$191 million and liabilities at 93.9% of assets. The refinancing's payment-in-kind feature saves more than $5 million of quarterly cash interest, which is real breathing room — but it is also why the equity moves so violently on cash news. So when the annual free-cash-flow milestone drifts, the stock listens. Back in August 2025: “we remain confident that we'll achieve EBITDA positive in the back half of the year and then ultimately cash flow positive next year.” — Rajbir Singh Denhoy, Chief Financial Officer · 2025-08-08 That "next year" was 2026. Today the first positive free-cash-flow year is 2027, even as the first positive free-cash-flow quarter finally landed. One quarter early on the quarter, one year late on the year — and a market that marks the latter.

Reconstruction is a free option that isn't in the number

What the tape may be underweighting is the pipeline. The reconstruction submission has cleared its biggest procedural hurdles: FDA information requests answered, BIMO inspections completed at multiple clinical sites including the sponsor site, and the approval process described as progressing as expected toward late 2026 or early 2027. The commercial groundwork is already laid — Motiva Flora tissue expanders are in more than 350 facilities, up 14% sequentially, and roughly 130 hospital accounts drive the majority of U.S. reconstruction volume. The gating item is administrative, not scientific: the VAC process, which management pegs at three to six months per facility. That is why the 25% growth guide for 2027 is explicitly back-half weighted and why, per CFO Cassandra Harris, “our 2027 outlook reflects our expectations for our business as a whole, including the opportunities across our portfolio” — Cassandra Harris, Chief Financial Officer · 2026-10-29 — reconstruction is upside, not the base. Management had been telegraphing this for a year, calling it “likely a 2027 and 2028 and beyond the story for us” — Rajbir Denhoy, Chief Financial Officer · 2026-02-24 even while the FDA review ran. Two quieter wins also landed. The long-negotiated long term agreement with silicone supplier NuSil — promised as a work-in-progress in May — is signed, with volume tiers and inflation-aligned pricing described as consistent with the prior contract. And the FDA cleared additional implant sizes, down to 105cc, opening roughly 10% of the U.S. market that was previously unaddressable and feeding the same utilization engine. Note the keyword migration there: small size slid down the board this quarter precisely as implant sizes climbed it — the aspiration became a product. The bear case is simply that a 10x-revenue, 94%-liabilities company guiding growth from ~30% to 25% needs everything to go right, and "everything" includes distributor timing, Middle East order flow, VAC committees and a PIK-supported cash ramp. The bull case is that this was the quarter the model proved it can generate cash at all. One of those is measurable in the next ninety days. The other isn't.